Summary: Giant cell tumor of the bone (GCTB) is usually a benign, locally aggressive tumor with metastatic potential. Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemotherapy regimens. Denosumab, which inhibits RANK-RANKL interaction, is a new, promising actor among targeted therapeutic agents for GCTB. In this report, we emphasize on early rapid response to denosumab in metastatic GCTB.
G iant cell tumor of the bone (GCTB) primarily occurs in young adults and presents as a lytic destructive lesion on the metaepiphyseal regions of long bones. It is usually a benign tumor but may present with high local aggressiveness, even with a risk for metastatic diseases, primarily to the lungs. 1, 2 Surgery is the preferred treatment option and it can be curative alone if performed adequately. Most local recurrences occur within the first 2 years after diagnosis. Progression of the disease is especially severe during the metastatic event. 2, 3 These patients still have poor prognosis, despite studies with several chemotherapeutic agents, interferon, and bisphosphonates. [1] [2] [3] [4] [5] [6] The pathophysiological studies of GCTB show high concentrations of RANK ligand (RANKL) in the neoplastic stromal cells. It seems to be rational to use a potential RANKL inhibitor in search for cure. Denosumab, a new, promising targeted therapeutic agent for GCTB, inhibits RANK-RANKL interaction, thus inhibiting the activation of the RANK-positive osteoclast-like giant cells and their precursors. 1, [7] [8] [9] 
CASE REPORT
Our patient, a 17-year-old girl, presented with a chief complaint of pain in the right knee. Radiograph and MRI showed expansile lytic osseous mass in the distal femur ( Fig. 1) and there was no metastatic nodule on thorax CT. The pathologic diagnosis of surgical biopsy was GCTB with typical histologic appearance (mononuclear stromal cells along with multinucleated giant cells) (Fig. 2) . After diagnosis, curettage and autologous bone grafting surgery were performed. Local recurrence was seen 3 months after primary surgery, and radical surgical resection of the distal femur and application of prosthesis were implemented. One month after the surgery, thorax CT showed bilateral numerous parenchymal pulmonary nodules. Varied chemotherapy regimens (ifosfamide, etoposide, carboplatin, adriamycin, and vincristine) and interferon a-2b were applied, all having failed. Finally, she had chest pain and hemoptysis with huge, progressive metastatic mass on chest CT (Fig. 3 ). Denosumab has been started, 120 mg per month, subcutaneously with oral vitamin D (400 IU daily), and calcium supplementation (500 mg daily). She did not have hypocalcemia and hypophosphatemia during the treatment period. After 2 doses of denosumab, she had no pulmonary symptoms, and thorax CT showed significant regression (> 50%) of the lung mass (Fig. 4) . She is still in the treatment protocol, and we observed 60% to 70% regression on thorax CT just after the third course of the therapy. We still need to look for long-term complications (high bone mineral density and osteonecrosis).
DISCUSSION
Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. 1, 3, 5 Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemotherapy regimens and interferon a-2b. 3, 6 RANKL is highly expressed by the stromal cells within GCTB, consistent with the hypothesis that RANKL expression is responsible for the pathologic recruitment of osteoclast-like cells. The RANKL inhibitor denosumab selectively binds to human RANKL. 7, 8 Karras et al 1 recently presented a 10-year-old girl with patellar GCTB with subcutaneous and multiple pulmonary metastatic nodules. After pathologic diagnosis, she was subsequently started on denosumab without primary surgery. Within 4 months of beginning the treatment, her pain markedly reduced, and 6 to 7 months into treatment she was back to her regular daily activities. On thorax CT, significant regression of the nodules, accepted as response, was seen. They also evaluated and showed the desirable histologic response of denosumab.
The latest large study, open-label phase 2 design, conducted on 282 GCTB patients (10 adolescents) by Chawla et al 9 showed a significant decrease in need for morbid surgery. In this report, an objective tumor response was noted in 72% of patients. Denosumab treatment delayed the immediate need for surgery in many patients with planned surgical interventions at study entry, and most patients either did not undergo surgery or underwent a less morbid surgical procedure than had been originally planned. Adverse events were consistent with the known safety profile of denosumab. Subsequently, Balke's 10 comment is interestingly noteworthy as much as the study of Chawla and colleagues. He noted that no well-designed studies considering bisphosphonates in GCTB have been conducted, and thus the superiority of denosumab can be only assumed rather than proved. He spotlights the funded study results of Chawla and colleagues to be controversial and calls for independent studies with longer follow-up periods. Otherwise, in the practice of pediatric oncology, it is hard to gather large patient groups together, especially for diseases such as GCTB. Case reports with successful results still have priority and should be considered inevitably to overcome the disease.
Karras et al 1 reported excellent clinical response with denosumab 120 mg, once per week for 3 weeks, followed by 120 mg monthly. We only used 120 mg monthly and we defined rapid objective response after 2 doses.
Denosumab seems to be a well-tolerated drug in the reports. 1, 7, 9 Most common side effects are hypocalcemia, hypophosphatemia, increased bone mineral density, risk for fracture, and osteonecrosis. 1, 7 In our patient, because of decreased bone turnover during denosumab treatment, we used prophylactic vitamin D and calcium supplementation. The patient has had no hypocalcemia or hypophosphatemia, but we still need to look for long-term complications.
In conclusion, we emphasize on early rapid response to denosumab in metastatic GCTB. It is probable that she would require long-term treatment with denosumab, as stated in Karras' report. What are the long-term response and effects of RANKL blockade in a young? And is 
